iiinova — where your digital self keeps evolving

ENCLAI

@enclai.net

Outbreak news by country, pharma & biotech news, and new medical studies explained. Daily, from official reports and published research, with the numbers and the source. enclai.net · RSS: enclai.net/news/rss Enclai LLC.

Posts Replies Media

ENCLAI @enclai.net · 01/10/2026

New: ENCLAI Evidence Digest, September 2026. Four developments that shaped the month, one per therapeutic area: Oncology · Respiratory · Neurology · Vaccines enclai.net/digest/2026-09

Cover of the ENCLAI Evidence Digest, September 2026

100

ENCLAI @enclai.net · 04/09/2026

GLP-1 RAs show substantial weight loss in adults without diabetes Systematic review / meta-analysis · Metabolic & endocrine · Annals of internal medicine · 2026-09-01 Authors report: Glucagon-like peptide-1… ENCLAI Daily → enclai.net/news #ClinicalResearch #Pharma #MedSky #MetabolicEndocrine

ENCLAI Daily infographic: GLP-1 RAs show substantial weight loss in adults without diabetes
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review
GLP-1 RAs show substantial weight loss in adults without diabetes. Systematic review / meta-analysis in Metabolic & endocrine — Annals of internal medicine. Authors report: Glucagon-like peptide-1 receptor agonists demonstrate substantial weight loss in adults without diabetes, with an expanding range of therapeutic options, including oral and multiagonist therapies.

010

ENCLAI @enclai.net · 04/09/2026

Eplontersen did not lower cardiovascular death or events in ATTR-CM Randomised trial · Phase 3 · Cardiovascular · NEJM · 2026-08-28 Authors report: Among patients with ATTR-CM, eplontersen therapy did not lead to a… ENCLAI Daily → enclai.net/news #ClinicalResearch #Pharma #MedSky #Cardiovascular

ENCLAI Daily infographic: Eplontersen did not lower cardiovascular death or events in ATTR-CM
Eplontersen for Transthyretin Amyloid Cardiomyopathy
Trial journey: 1432 patients · Randomised 1:1 · vs Placebo · Double-blind · follow-up up to week 140.
Primary endpoint: a cumulative composite of death from cardiovascular causes and recurrent cardiovascular clinical events up to week 140.
Eplontersen did not lower cardiovascular death or events in ATTR-CM. Randomised trial · Phase 3 in Cardiovascular — NEJM. Authors report: Among patients with ATTR-CM, eplontersen therapy did not lead to a lower risk of a composite of death from cardiovascular causes and recurrent cardiovascular events than placebo up to 140 weeks.

010

ENCLAI @enclai.net · 04/09/2026

Epcoritamab plus rituximab-lenalidomide shows high activity in first-line follicular lymphoma Early-phase / non-randomised trial · Phase 1/2 · Oncology · Lancet Haematology · 2026-09-01 Authors report: Epcoritamab plus… ENCLAI Daily → enclai.net/news #ClinicalResearch #Pharma #MedSky #Oncology

ENCLAI Daily infographic: Epcoritamab plus rituximab-lenalidomide shows high activity in first-line follicular lymphoma
Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial
Trial journey: 41 patients · Open-label · follow-up median 35·9 months.
Primary endpoint: investigator-assessed overall response rate by Lugano Response Criteria for Malignant Lymphoma.
Epcoritamab plus rituximab-lenalidomide shows high activity in first-line follicular lymphoma. Early-phase / non-randomised trial · Phase 1/2 in Oncology — Lancet Haematology. Authors report: Epcoritamab plus rituximab-lenalidomide showed high activity in first-line treatment for follicular lymphoma, with 95% of patients having a response over 3 years of follow-up, supporting this treatment…

010

ENCLAI @enclai.net · 04/09/2026

AAP recommends single 2026-2027 dose for healthy children 2-18 Guidelines & recommendations · Infectious disease · Pediatrics · 2026-09-02 Authors report: Children 2 through 18 years of age not considered… ENCLAI Daily → enclai.net/news #ClinicalResearch #Pharma #MedSky #InfectiousDisease #Covid19

ENCLAI Daily infographic: AAP recommends single 2026-2027 dose for healthy children 2-18
Recommendations for COVID-19 Vaccines in Infants, Children, and Adolescents, 2026-2027: Policy Statement
AAP recommends single 2026-2027 dose for healthy children 2-18. Guidelines & recommendations in Infectious disease — Pediatrics. Authors report: Children 2 through 18 years of age not considered at increased risk of severe COVID-19 whose parent or guardian desires their protection from COVID-19 should be offered a single dose of age-appropriate 2026-2027 COVID-19 vaccine. Any available COVID-19…

010

ENCLAI @enclai.net · 04/09/2026

STRIDE plus lenvatinib plus TACE showed a statistically significant progression-free survival improvement Randomised trial · Phase 3 · Oncology · Lancet Oncology · 2026-09-01 Authors report: STRIDE plus lenvatinib plus… ENCLAI Daily → enclai.net/news #ClinicalResearch #Pharma #MedSky #Oncology

ENCLAI Daily infographic: STRIDE plus lenvatinib plus TACE showed a statistically significant progression-free survival improvement
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
Trial journey: 760 participants · Randomised 1:1:1 · vs TACE · Open-label (sponsor-blinded) · follow-up median 10·0 months.
Primary endpoint: progression-free survival for STRIDE plus lenvatinib plus TACE versus TACE.
STRIDE plus lenvatinib plus TACE showed a statistically significant progression-free survival improvement. Randomised trial · Phase 3 in Oncology — Lancet Oncology. Authors report: STRIDE plus lenvatinib plus TACE showed a statistically significant progression-free survival improvement versus TACE. These findings support a STRIDE-based regimen as a potential new treatment option for people with…

010